The Jensen Lab is interested in both benign and malignant brain tumor angiogenesis, biology, and developing novel treatment modalities for these tumors. The first emphasis is on the role of hypoxia-inducible factor-1 (HIF-1) in malignant brain tumor angiogenesis and growth. We are currently using siRNA techniques to inhibit HIF-1 in mouse tumor models with hopes of initiating human clinical trials in the near future. A second emphasis is toward an understanding of the biology of and the treatment of unresectable or recurrent meningiomas. Current investigations include the use of calcium channel antagonists to potentiate common chemotherapeutic approaches to the treatment of meningiomas. We have also examined the role of COX-2 in meningioma development and growth. We have successfully inhibited the growth of meningiomas with COX-2 inhibitors. To better understand meningioma biology, we have developed animal models and evaluated currently available cell lines. Our hope is to provide cutting-edge approaches to treat both benign and malignant brain tumors and transition these to Phase I Human clinical trials.